Navigation Links
Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum
Date:4/17/2014

NEW YORK (17 April 2014) Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study also provides the first data that the gel is effective against multiple strains of HIV, and has a window of efficacy in the vagina against all three viruses of at least eight hours prior to exposure. A Phase 1 safety trial of the gel is set to begin enrollment in May 2014.

These findings were published today in PLOS ONE in an article entitled "A Potent Combination Microbicide that Targets SHIV-RT, HSV-2 and HPV."

The gel, known as MZC, contains two potent antiviral agents: MIV-150 and zinc acetate. MIV-150 is an enzyme inhibitor that prevents HIV-infected cells from producing new virus, and zinc acetate is an antiviral agent with known activity against HIV and HSV-2. These compounds are mixed in a base of carrageenan, a compound derived from seaweed that has also been shown to have potent activity against HPV. Infection with HSV-2 or HPV is associated with increased risk of HIV infection. Microbicides that target HIV, HSV-2, and HPV may more effectively limit HIV transmission than those that target HIV alone.

In this study, Council scientists and their partners used macaque and mouse models to examine whether MZC gel could prevent the vaginal and rectal transmission of SHIV-RT, HSV-2, and HPV. SHIV-RT is a human/simian immunodeficiency chimeric virus combining the HIV reverse transcriptase (RT) within SIV (the monkey version of HIV). MIV-150 and zinc acetate inhibit HIV-RT via different mechanisms of action. Preclinical testing in animals is required by the FDA and is important to ensure the highest level of safety and to build the evidence base for potential efficacy in
'/>"/>

Contact: Melanie Boyer
mboyer@popcouncil.org
202-237-9404
Population Council
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Researchers develop a new cell and animal model of inflammatory breast cancer
2. FDA Seeks to Limit Antibiotics in Animal Feed
3. Animals More Interesting to Kids Than Toys, Study Shows
4. Raucous Music May Tap Into Your Inner Animal
5. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
6. Woodbridge Animal Hospital Unleashes New Pet Care Website
7. Chicago Dog Bite Injury Lawyers Advise Dog Owners To Get Control of Their Animals, Or Be Prepared To Pay Up
8. New technique could reduce number of animals needed to test chemical safety
9. Potential treatment target identified in an animal model of pancreatic cancer
10. New animal model may lead to treatments for common liver disease
11. Lab-engineered muscle implants restore function in animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014 Recently, BambooIndustry.com, a professional company ... collection of bamboo floors . What’s more, the ... of its products at the moment. According to the ... 26 percent off. The promotion will be valid until ... http://www.bambooindustry.com ) are all made by qualified workers. A ...
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product manufacturer ... appreciation from the global customers in the past few ... more excellent items. All its online workers are professional ... , The company has recently added a new ... Furthermore, the company’s marketing specialist has announced that all ...
(Date:10/2/2014)... Children with autism are more sedentary than those without ... active, a small study suggests. Researchers tested the ... autism and some without. Children with autism averaged 50 ... 70 more minutes each day sitting than those without ... on strength, but had similar body-mass index (a measurement ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... the District of Columbia now have a total of 500 ... has been infecting children since the summer, U.S. health ... have died in recent weeks, but it,s not clear what ... deaths, officials said. Health officials are also trying to ...
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2
... method cuts death risk, study finds , WEDNESDAY, Aug. ... who receive early non-invasive ventilation after a breathing tube ... failure or die, a Spanish study has found. , ... of them had high levels of carbon dioxide in ...
... behind progress, study finds , THURSDAY, Aug. 13 (HealthDay ... younger people, new research shows. , And while cancer ... the United States, topping heart disease, that is because ... cancer. , "Older Americans have only experienced decreased [cancer] ...
... YORK, Aug. 13 The International Longevity Center, with support ... $20,000 grants for caregiver training programs. , , ... Initiative grants are part of the Caregiving Project for ... the Schmieding Center for Senior Health and Education. The initiative ...
... , , BALTIMORE, Aug. ... Maryland, the Black Nurses Association of Baltimore and the Greater ... Health Insurer Code of Conduct from the American Medical Association. ... portion of the state,s racial and ethnic minorities, including African ...
... , THOUSAND OAKS, Calif., Aug. 13 ... data from the submitted Biologic License Applications (BLAs) for denosumab for ... treatment of bone loss in breast and prostate cancer patients undergoing ... Administration,s (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD). , ...
... RICHMOND, Va., Aug. 13 Insmed Inc. (Nasdaq: ... second quarter and six-months ended June 30, 2009. , , ... were $3.0 million, up from $2.7 million for the corresponding period ... grant revenue related to the IPLEX(TM) myotonic muscular dystrophy ("MMD") clinical ...
Cached Medicine News:Health News:Ventilation After Breathing Tube Removal May Alter Outcomes 2Health News:Cancer Deaths Declining, Especially Among Young 2Health News:Cancer Deaths Declining, Especially Among Young 3Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 2Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 3Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 4Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 5Health News:Leading African American Groups Call On Health Insurers to Dismiss Restrictive Practices 2Health News:Leading African American Groups Call On Health Insurers to Dismiss Restrictive Practices 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 2Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 4Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 5Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 6Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 7Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 2Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 3Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 4Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 5Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 6Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 7Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 8Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 9
(Date:10/2/2014)... 1, 2014   Intarcia Therapeutics, Inc. today ... phase 3 clinical trials for ITCA 650 (exenatide, delivered ... osmotic mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, ... and safety of ITCA 650 in patients with type ... to be significantly superior to placebo for both 40 ...
(Date:10/1/2014)... and NOTTINGHAM, England , Oct. ... CBRX ) today announced that its subsidiary, Molecular Profiles ... Trials platform at the annual CPhI/ICSE Worldwide event in ... to support companies with the rapid development of both ... enabling technologies screening platform, which incorporates the company,s existing ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... FLEX ) is expanding its medical disposables offering ... through a share purchase agreement. Slomedical is a leading ... sets to complex devices for minimally-invasive surgery. This deal ... calendar year, pending required regulatory clearances. , Upon ...
... , CLINTON, N.J., Oct. 21 Ikaria Holdings, Inc. ... Award for Excellence in Business Expansion by the New ... employer association in the United States. Ikaria earned ... revenues, as well as the net creation of new ...
Cached Medicine Technology:Flextronics Announces Expansion of Medical Disposables Offering 2Ikaria Receives Award for Excellence by New Jersey Business & Industry Association 2
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
...
Designed for stab incisions...
Medicine Products: